Andrew Tsai
Stock Analyst at Jefferies
(1.41)
# 2,428
Out of 4,479 analysts
12
Total ratings
45.45%
Success rate
9.7%
Average return
Main Sectors:
11 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Initiates: Buy | $33 | $11.40 | +189.47% | 1 | Feb 27, 2024 | |
| VTGN VistaGen Therapeutics | Upgrades: Buy | $0.2 → $15 | $3.57 | +320.17% | 2 | Dec 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Initiates: Hold | $3 | $1.68 | +79.10% | 1 | Mar 7, 2023 | |
| ATHA Athira Pharma | Downgrades: Hold | $32 → $3 | $2.51 | +19.52% | 1 | Jun 23, 2022 | |
| BEKE KE Holdings | Upgrades: Overweight | $23 → $16 | $14.78 | +8.25% | 1 | Mar 16, 2022 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $20 | $4.37 | +357.67% | 1 | Feb 1, 2022 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | n/a | $67.99 | - | 1 | Sep 20, 2021 | |
| ATAI Atai Life Sciences | Initiates: Buy | n/a | $1.35 | - | 1 | Sep 1, 2021 | |
| CERE Cerevel Therapeutics Holdings | Initiates: Buy | n/a | $41.35 | - | 1 | Nov 23, 2020 | |
| XENE Xenon Pharmaceuticals | Assumes: Buy | n/a | $37.69 | - | 1 | Jun 1, 2020 | |
| RLMD Relmada Therapeutics | Initiates: Buy | n/a | $3.07 | - | 1 | Jan 27, 2020 |
Alto Neuroscience
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $11.40
Upside: +189.47%
VistaGen Therapeutics
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $3.57
Upside: +320.17%
Lexicon Pharmaceuticals
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.68
Upside: +79.10%
Athira Pharma
Jun 23, 2022
Downgrades: Hold
Price Target: $32 → $3
Current: $2.51
Upside: +19.52%
KE Holdings
Mar 16, 2022
Upgrades: Overweight
Price Target: $23 → $16
Current: $14.78
Upside: +8.25%
Vigil Neuroscience
Feb 1, 2022
Initiates: Buy
Price Target: $20
Current: $4.37
Upside: +357.67%
Intra-Cellular Therapies
Sep 20, 2021
Maintains: Buy
Price Target: n/a
Current: $67.99
Upside: -
Atai Life Sciences
Sep 1, 2021
Initiates: Buy
Price Target: n/a
Current: $1.35
Upside: -
Cerevel Therapeutics Holdings
Nov 23, 2020
Initiates: Buy
Price Target: n/a
Current: $41.35
Upside: -
Xenon Pharmaceuticals
Jun 1, 2020
Assumes: Buy
Price Target: n/a
Current: $37.69
Upside: -
Relmada Therapeutics
Jan 27, 2020
Initiates: Buy
Price Target: n/a
Current: $3.07
Upside: -